CN1416425A - 1,5－苯并硫氮杂䓬及其它们作为促血清脂质降低剂的用途 - Google Patents

1,5－苯并硫氮杂䓬及其它们作为促血清脂质降低剂的用途 Download PDF

Info

Publication number
CN1416425A
CN1416425A CN01806160A CN01806160A CN1416425A CN 1416425 A CN1416425 A CN 1416425A CN 01806160 A CN01806160 A CN 01806160A CN 01806160 A CN01806160 A CN 01806160A CN 1416425 A CN1416425 A CN 1416425A
Authority
CN
China
Prior art keywords
alkyl
solvate
formula
group
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01806160A
Other languages
English (en)
Chinese (zh)
Inventor
I·斯塔克
M·达尔斯特伦
D·布洛姆贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1416425A publication Critical patent/CN1416425A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CN01806160A 2000-03-08 2001-03-05 1,5－苯并硫氮杂䓬及其它们作为促血清脂质降低剂的用途 Pending CN1416425A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000772A SE0000772D0 (sv) 2000-03-08 2000-03-08 Chemical compounds
SE00007724 2000-03-08

Publications (1)

Publication Number Publication Date
CN1416425A true CN1416425A (zh) 2003-05-07

Family

ID=20278738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01806160A Pending CN1416425A (zh) 2000-03-08 2001-03-05 1,5－苯并硫氮杂䓬及其它们作为促血清脂质降低剂的用途

Country Status (17)

Country Link
US (1) US6906058B2 (https=)
EP (1) EP1263747B1 (https=)
JP (1) JP5204361B2 (https=)
KR (1) KR20020079990A (https=)
CN (1) CN1416425A (https=)
AT (1) ATE283266T1 (https=)
AU (2) AU3755601A (https=)
BR (1) BR0109011A (https=)
CA (1) CA2401055A1 (https=)
DE (1) DE60107395T2 (https=)
IL (1) IL151296A0 (https=)
MX (1) MXPA02008600A (https=)
NO (1) NO20024217L (https=)
NZ (1) NZ520951A (https=)
SE (1) SE0000772D0 (https=)
WO (1) WO2001066533A1 (https=)
ZA (1) ZA200206739B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573902A (zh) * 2014-10-20 2017-04-19 Cj医药健康株式会社 新型氨基烷基苯并硫氮杂*衍生物及其用途
CN116157389A (zh) * 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
AU2003203482B2 (en) 2002-04-09 2005-06-02 Syngenta Participations Ag Process for the preparation of cyclic diketones
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
PL375074A1 (en) * 2002-06-20 2005-11-14 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
AU2008221673B2 (en) * 2007-03-08 2013-03-28 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
CA2744817C (en) * 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
JP6097695B2 (ja) 2010-11-08 2017-03-15 アルビレオ アクチエボラグ Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
KR101844184B1 (ko) 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
ES2955799T3 (es) * 2019-02-06 2023-12-07 Albireo Ab Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
PL3923943T3 (pl) 2019-02-12 2024-12-09 Mirum Pharmaceuticals, Inc. Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
JP7689076B2 (ja) 2019-09-09 2025-06-05 Ｅａファーマ株式会社 １，５－ベンゾチアゼピン化合物を製造するための方法
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) * 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
CN119487013A (zh) * 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US20240173333A1 (en) 2022-11-03 2024-05-30 Albireo Ab Treating Alagille Syndrome (ALGS)
WO2025093760A1 (en) 2023-11-03 2025-05-08 Albireo Ab Treating pfic2 with odevixibat
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
DK0781278T3 (da) 1994-09-13 2001-04-17 Monsanto Co Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) * 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
NZ331813A (en) 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
MXPA99008417A (es) 1997-03-11 2005-02-03 Searle & Co Terapia de combinacion que emplaza benzotiepinas inhibidoras de transporte de acido biliar ileal e inhibidores de hmg co-a reductasa.
DE69815180T2 (de) 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
AU1944099A (en) 1997-12-31 1999-07-19 Infodream Corporation Bubble edit
GB9800428D0 (en) * 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1140191B1 (en) 1998-12-23 2002-10-23 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
CN1342090A (zh) 1998-12-23 2002-03-27 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
CA2362147A1 (en) 1999-02-12 2000-08-17 Steve A. Kolodziej 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
AU784722B2 (en) 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
AU2001247331A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573902A (zh) * 2014-10-20 2017-04-19 Cj医药健康株式会社 新型氨基烷基苯并硫氮杂*衍生物及其用途
CN106573902B (zh) * 2014-10-20 2019-10-08 Cj医药健康株式会社 氨基烷基苯并硫氮杂*衍生物及其用途
CN116157389A (zh) * 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Also Published As

Publication number Publication date
SE0000772D0 (sv) 2000-03-08
BR0109011A (pt) 2003-06-03
MXPA02008600A (es) 2003-02-24
CA2401055A1 (en) 2001-09-13
DE60107395D1 (de) 2004-12-30
EP1263747A1 (en) 2002-12-11
WO2001066533A1 (en) 2001-09-13
AU3755601A (en) 2001-09-17
KR20020079990A (ko) 2002-10-21
ATE283266T1 (de) 2004-12-15
JP5204361B2 (ja) 2013-06-05
NO20024217D0 (no) 2002-09-04
ZA200206739B (en) 2003-11-24
EP1263747B1 (en) 2004-11-24
NZ520951A (en) 2004-05-28
US6906058B2 (en) 2005-06-14
AU2001237556B2 (en) 2004-10-07
NO20024217L (no) 2002-10-09
US20030166927A1 (en) 2003-09-04
IL151296A0 (en) 2003-04-10
DE60107395T2 (de) 2005-12-01
JP2003525933A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
CN1416425A (zh) 1,5－苯并硫氮杂䓬及其它们作为促血清脂质降低剂的用途
CN1149209C (zh) 与多巴胺d3受体具有亲和力的三唑化合物
CN1072220C (zh) 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1104419C (zh) 苯并吖庚因衍生物
CN1253449C (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
CN1582283A (zh) 苯并硫杂庚英回肠胆汁酸转运抑制剂
CN1052231C (zh) 2－氧代－5－噁唑烷酮甲基化合物,它们的制备方法及含它们的药物组合物
CN1097052C (zh) 脒吲哚衍生物及其盐的制备方法
CN1058710C (zh) 苯甲酰胺衍生物及其制法、用途和含其的药物组合物
CN1662514A (zh) 苯并硫杂二氮杂䓬衍生物、它们的制备方法以及包含它们的药用组合物
CN1228087A (zh) 取代的嘧啶衍生物和它们的药物用途
CN1659182A (zh) 用于治疗高脂血症的包含硫氮杂䓬基团的肽衍生物
CN1599731A (zh) 苯并硫氮杂䓬衍生物
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1106397A (zh) 稠环化合物及其用途
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1481373A (zh) 1,5-苯并硫氮杂�化合物及其作为降血脂药的应用
CN1192729A (zh) 苯甲酰胺衍生物和它们作为后叶加压素拮抗剂的应用
CN86102738A (zh) 新的含硫5-取代苯并咪唑衍生物的制备方法
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1246850A (zh) 1,5－苯并二氮杂衍生物
CN1535968A (zh) 四氢吡啶基或哌啶基杂环衍生物
CN1083481A (zh) 4，1-苯并氧氮杂䓬衍生物和其用途
CN1051766C (zh) 血管紧张素ⅱ拮抗剂咪唑衍生物，它们的制备及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication